Creating a Life Science and Diagnostics Leader Focused on Regulated, High-Volume Testing

Transaction Overview

On July 14, 2025, Waters and BD announced a definitive agreement to combine BD’s Biosciences & Diagnostic Solutions business with Waters through a tax-efficient Reverse Morris Trust transaction.

Large TAM with consistent growth drivers; doubles TAM to ~$40B at 5-7% growth in a broader range of regulated sources
Accelerates expansion into multiple high-growth adjacent end-markets, including bioanalytical characterization, bioseparations, and multiplex diagnostics
Immediate commercial impact from Waters’ proven execution model of instrument replacement, service plan attachment, e-commerce adoption, and launch excellence
Increases growth stability; over 70% of revenue annually recurring with over 50% of instruments replaced every 5-10 years

Compelling Value Creation Opportunity

Industry-Leading 5-Year Financial Outlook

EXPECTED
MSD-HSD
Revenue growth
Mid-teens%
Adj. EPS growth
~500bps
Adj. operating margin expansion

Rapid Adj. EPS Accretion and Significant Synergies

EXPECTED
$200M
Cost synergies by year 3
$290M
Revenue synergies by year 5
Accretive
to Adj. EPS in first year

Investor Presentation

“Waters and BD Biosciences & Diagnostic Solutions share a rich legacy of innovation, complementary expertise in regulated, high-volume settings, and a deep commitment to science and solving customers’ unmet needs. Together, this combination will create a more diversified company with best-in class technologies, industry-leading financials, and a clear runway for sustainable, long-term growth.”
Udit Batra
Waters President & Chief Executive Officer
“We are bringing together complementary portfolios and channels that create an industry leading life science and diagnostics company. We see an incredible opportunity to leverage both companies’ commitments to unparalleled innovation, technology, and commercial presence to serve attractive, high-growth end-markets, while simultaneously unlocking multiple new growth vectors.”
Tom Polen
BD Chairman, CEO & President